参考文献/References:
[1] Palomba S, Santagni S, Falbo A, et al. Complications and challenges associated with polycystic ovary syndrome: currentperspectives[J].Int J Womens Health,2015,7:745-763. DOI: 10.2147/IJWH.S70314.
[2] Aydin K, Arusoglu G, Koksal G,et al. Fasting and post-prandial glucagon like peptide 1 and oral contraception in polycystic ovary syndrome[J].Clin Endocrinol(Oxf),2014,81(4):588-592. DOI: 10.1111/cen.12468.
[3] Spritzer PM, Lecke SB, Satler F,et al. Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome[J].Reproduction,2015,149(5):R219-R227. DOI: 10.1530/REP-14-0435.
[4] Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome[J].Mol Cell Endocrinol,2011,335(1):30-41. DOI: 10.1016/j.mce.2010.08.002.
[5] Plati E, Kouskouni E, Malamitsi-Puchner A,et al. Visfatin and leptin levels in women with polycystic ovaries undergoing ovarian stimulation[J].Fertil Steril,2010,94(4):1451-1456. DOI: 10.1016/j.fertnstert.2009.04.055.
[6] Cekmez F, Cekmez Y, Pirgon O,et al. Evaluation of new adipocytokines and insulin resistance in adolescents with polycystic ovarysyndrome[J].Eur Cytokine Netw,2011,22(1):32-37. DOI: 10.1684/ecn.2011.0279.
[7] Seow KM, Hwang JL, Wang PH,et al. Expression of visfatin mRNA in peripheral blood mononuclear cells is not correlated with visfatin mRNA in omental adipose tissue in women with polycystic ovary syndrome[J].Hum Reprod,2011,26(10):2869-2873. DOI: 10.1093/humrep/der267.
[8] Tombran-Tink J, Barnstable CJ. PEDF: a multifaceted neurotrophic factor[J].Nat Rev Neurosci,2003,4(8):628-636.DOI:10.1038/nrn1176.
[9] Yang SJ, Hwang SY, Choi HY,et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: implications for insulin resistance, inflammation, and atherosclerosis[J].J Clin Endocrinol Metab,2011,96(8):E1325-E1329. DOI: 10.1210/jc.2011-0620.
[10] Rojas J, Chávez M, Olivar L,et al. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologiclabyrinth[J].Int J Reprod Med,2014,2014:719050. DOI: 10.1155/2014/719050.
[11] Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms andimplications[J].Endocr Rev,2012,33(6):981-1030. DOI: 10.1210/er.2011-1034.
[12] Legro RS. Obesity and PCOS: implications for diagnosis and treatment[J].Semin Reprod Med,2012,30(6):496-506. DOI: 10.1055/s-0032-1328878.
[13] Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective[J].Front Biosci(Elite Ed),2014,6:104-119.
[14] Ebrahimi-Mamaghani M, Saghafi-Asl M, Pirouzpanah S,et al. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome[J].J Health Popul Nutr,2015,33(1):157-167.
[15] Lerchbaum E, Schwetz V, Giuliani A,et al. Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome[J].Fertil Steril,2012,98(5):1318-1325. DOI: 10.1016/j.fertnstert.2012.07.1057.
[16] Meloni AR, DeYoung MB, Lowe C,et al. GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence[J].Diabetes Obes Metab,2013,15(1):15-27. DOI: 10.1111/j.1463-1326.2012.01663.x.
[17] Ding SY, Nkobena A, Kraft CA,et al. Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic betacells[J].J Biol Chem,2011,286(19):16768-16774. DOI: 10.1074/jbc.M110.192799.
[18] Lee YS, Park MS, Choung JS,et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J].Diabetologia,2012,55(9):2456-2468. DOI: 10.1007/s00125-012-2592-3.
[19] Nakamura K, Oe H, Kihara H,et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study[J].Cardiovasc Diabetol,2014,13:110. DOI: 10.1186/s12933-014-0110-2.
[20] Hsieh J, Longuet C, Baker CL,et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice[J].Diabetologia,2010,53(3):552-561. DOI: 10.1007/s00125-009-1611-5.
[21] Niafar M, Pourafkari L, Porhomayon J,et al. A systematic review of GLP-1 agonists on the metabolic syndrome in women with polycystic ovaries[J].Arch Gynecol Obstet,2016,293(3):509-515. DOI: 10.1007/s00404-015-3976-7.
[22] Pyke C, Heller RS, Kirk RK,et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody[J].Endocrinology,2014,155(4):1280-1290. DOI: 10.1210/en.2013-1934.
[23] Dailey MJ, Moran TH. Glucagon-like peptide 1 and appetite[J].Trends Endocrinol Metab,2013,24(2):85-91. DOI: 10.1016/j.tem.2012.11.008.
[24] Richards P, Parker HE, Adriaenssens AE,et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenicmouse model[J].Diabetes,2014,63(4):1224-1233. DOI: 10.2337/db13-1440.
[25] Maida A, Lamont BJ, Cao X,et al. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice[J].Diabetologia,2011,54(2):339-349. DOI: 10.1007/s00125-010-1937-z.
[26] Jensterle Sever M, Kocjan T, Pfeifer M,et al. Short-term combined treatment with liraglutide and metformin leads to significant weight loss inobese women with polycystic ovary syndrome and previous poor response to metformin[J].Eur J Endocrinol,2014,170(3):451-459. DOI: 10.1530/EJE-13-0797.
[27] Jensterle M, Kravos NA, Pfeifer M,et al. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome[J].Hormones(Athens),2015,14(1):81-90.
[28] Orvieto R, Meltcer S, Liberty G,et al. Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue [J].Gynecol Endocrinol,2012,28(6):422-424. DOI: 10.3109/09513590.2011.633661.
[29] 王璐. 胰高血糖素样肽1受体激动剂治疗伴胰岛素抵抗的多囊卵巢综合症的疗效研究[D].吉林大学,2013.
[30] Elkind-Hirsch K, Marrioneaux O, Bhushan M,et al. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome[J].J Clin Endocrinol Metab,2008,93(7):2670-2678. DOI: 10.1210/jc.2008-0115.
[31] Moran LJ, Misso ML, Wild RA,et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis[J].Hum Reprod Update,2010,16(4):347-363. DOI: 10.1093/humupd/dmq001.
[32] Wang ET, Calderon-Margalit R, Cedars MI,et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia[J].Obstet Gynecol,2011,117(1):6-13. DOI: 10.1097/AOG.0b013e31820209bb.
[33] Cariou B. Harnessing the incretin system beyond glucose control: potential cardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes[J].Diabetes Metab,2012,38(4):298-308. DOI: 10.1016/j.diabet.2012.04.003.
[34] Toulis KA, Goulis DG, Mintziori G,et al. Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome[J].Hum Reprod Update,2011,17(6):741-760. DOI: 10.1093/humupd/dmr025.
[35] Nikolaidis LA, Elahi D, Shen YT,et al. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy[J].Am J Physiol Heart Circ Physiol,2005,289(6):H2401-H2408. DOI:10.1152/ajpheart.00347.2005.
[36] Laviola L, Leonardini A, Melchiorre M,et al. Glucagon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiacprogenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway[J].Endocrinology,2012,153(12):5770-5781. DOI: 10.1210/en.2012-1461.
[37] Mikhail N. Effects of incretin-based therapy in patients with heart failure and myocardial infarction[J].Endocrine,2014,47(1):21-28. DOI: 10.1007/s12020-014-0175-4.
[38] Kahal H, Aburima A, Ungvari T,et al. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls[J].BMC Endocr Disord,2015,15:14. DOI: 10.1186/s12902-015-0005-6.
[39] Baranova A, Tran TP, Birerdinc A,et al. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease[J].Aliment Pharmacol Ther,2011,33(7):801-814. DOI: 10.1111/j.1365-2036.2011.04579.x.
[40] Ma RC, Liu KH, Lam PM,et al. Sonographic measurement of mesenteric fat predicts presence of fatty liver among subjects with polycystic ovary syndrome[J].J Clin Endocrinol Metab,2011,96(3):799-807. DOI: 10.1210/jc.2010-1608.
[41] Borruel S, Fernández-Durán E, Alpan～és M, et al. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome(PCOS)[J].J Clin Endocrinol Metab,2013,98(3):1254-1263. DOI: 10.1210/jc.2012-3698.
[42] Kahal H, Abouda G, Rigby AS,et al. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease[J].Clin Endocrinol(Oxf),2014,81(4):523-528. DOI: 10.1111/cen.12369.
相似文献/References:
[1]曹琳,杨昱,刘超.减重手术对多囊卵巢综合征的治疗作用[J].国际内分泌代谢杂志,2014,(06):415.[doi:10.3760/cma.j.issn.1673-4157.2014.06.015]
Cao Lin,Yang Yu,Liu Chao..Therapeutic effects of bariatric surgery on polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(03):415.[doi:10.3760/cma.j.issn.1673-4157.2014.06.015]
[2]杨健姝,华飞,唐暎,等.二甲双胍在多囊卵巢综合征患者妊娠期的应用[J].国际内分泌代谢杂志,2014,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
Yang Jianshu,Hua Fei,Tang Ying,et al.The application of metformin in the pregnant patients with polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2014,(03):176.[doi:10.3760/cma.j.issn.1673-4157.2014.03.009]
[3]周欢欢,徐书杭,刘超,等.肠促胰素类降糖药物对体重的作用[J].国际内分泌代谢杂志,2016,36(03):172.[doi:10.3760/cma.j.issn.1673-4157.2016.03.07]
Zhou Huanhuan*,Xu Shuhang,Liu Chao,et al.Effects of incretin drugs on body weight[J].International Journal of Endocrinology and Metabolism,2016,36(03):172.[doi:10.3760/cma.j.issn.1673-4157.2016.03.07]
[4]司马盼盼 孙良阁.多囊卵巢综合征与自身免疫性甲状腺疾病的相关性[J].国际内分泌代谢杂志,2018,38(03):163.[doi:10.3760/cma.j.issn.1673-4157.2018.03.005]
Sima Panpan,Sun Liangge..Correlation between polycystic ovary syndrome and autoimmune thyroid disease[J].International Journal of Endocrinology and Metabolism,2018,38(03):163.[doi:10.3760/cma.j.issn.1673-4157.2018.03.005]
[5]廖鑫 张开羽 高琳 张晗 张琳 邓凡曲 黄琦 李思成 张凌.多囊卵巢综合征患者血清PTX3、vaspin
水平的观察研究[J].国际内分泌代谢杂志,2018,38(04):228.[doi:10.3760/cma.j.issn.1673-4157.2018.04.003]
Liao Xin*,Zhang Kaiyu,Gao Lin,et al.Study of serum PTX3 and vaspin levels in patients with polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2018,38(03):228.[doi:10.3760/cma.j.issn.1673-4157.2018.04.003]
[6]袁铖 华飞.Th1/Th2失衡与多囊卵巢综合征[J].国际内分泌代谢杂志,2020,40(01):59.[doi:10.3760/cma.j.issn.1673-4157.2020.01.014]
Yuan Cheng,Hua Fei.Th1/Th2 imbalance and polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2020,40(03):59.[doi:10.3760/cma.j.issn.1673-4157.2020.01.014]
[7]叶赛,鲁一兵.肠道激素多受体激动剂治疗代谢性疾病的研究进展[J].国际内分泌代谢杂志,2022,42(06):477.[doi:10.3760/cma.j.cn121383-20211009-10013]
Ye Sai,Lu Yibing..Progress of intestinal hormone multi-receptor agonists in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2022,42(03):477.[doi:10.3760/cma.j.cn121383-20211009-10013]
[8]梁杏燕,赵捷,马红霞.自身免疫性甲状腺疾病对多囊卵巢综合征不良妊娠结局的影响[J].国际内分泌代谢杂志,2022,42(06):481.[doi:10.3760/cma.j.cn121383-20211016-10036]
Liang Xingyan,Zhao Jie,Ma Hongxia..Influence of autoimmune thyroid disease on adverse pregnant outcome in polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2022,42(03):481.[doi:10.3760/cma.j.cn121383-20211016-10036]
[9]车悦,陶弢.饮食干预对多囊卵巢综合征患者生殖功能影响的研究进展[J].国际内分泌代谢杂志,2023,43(01):62.[doi:10.3760/cma.j.cn121383-20211002-10001]
Che Yue,Tao Tao..Research progress of dietary intervention impact on reproduction in polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2023,43(03):62.[doi:10.3760/cma.j.cn121383-20211002-10001]
[10]蒋艺婕,杜科,华飞.铁代谢异常及铁死亡与多囊卵巢综合征关系的研究进展[J].国际内分泌代谢杂志,2023,43(02):124.[doi:10.3760/cma.j.cn121383-20220122-01046]
Jiang Yijie,Du Ke,Hua Fei..Relationship between abnormal iron metabolism, ferroptosis and polycystic ovary syndrome[J].International Journal of Endocrinology and Metabolism,2023,43(03):124.[doi:10.3760/cma.j.cn121383-20220122-01046]